首页> 外文期刊>Prostate International >Epidemiology of prostate cancer in the Asia-Pacific region
【24h】

Epidemiology of prostate cancer in the Asia-Pacific region

机译:亚太地区前列腺癌的流行病学

获取原文
           

摘要

The purpose of this paper was to examine and compare available data on incidence, mortality and survival for countries in the Asia-Pacific region. Incidence data were obtained from GLOBOCAN 2008, other online data sources and individual cancer registries. Country-specific mortality statistics by individual year were sourced from the World Health Organization Statistical Information System Mortality Database. All incidence and mortality rates were directly age-standardised to the Segi World Standard population and joinpoint models were used to assess trends. Data on survival were obtained from country-specific published reports where available. Approximately 14% (122,000) of all prostate cancers diagnosed worldwide in 2008 were within the Asia-Pacific region (10 per 100,000 population), with three out of every four of these prostate cancer cases diagnosed in either Japan (32%), China (28%) or Australia (15%). There were also about 42,000 deaths due to prostate cancer in the Asia-Pacific region (3 per 100,000). For the nine countries with incidence trend data available, eight showed recent significant increases in prostate cancer incidence. In contrast, recent decreases in prostate cancer mortality have been reported for Australia, Japan and New Zealand, but mortality has increased in several other countries. The lack of population-based data across most of the countries in this region limits the ability of researchers to understand and report on the patterns and distribution of this important cancer. Governments and health planners typically require quantitative evidence as a motivation for change. Unless there is a widespread commitment to improve the collection and reporting of data on prostate cancer it is likely that the burden of prostate cancer will continue to increase. Enhancing knowledge transfer between countries where there are differentials in capacity, policy and experience may provide the necessary impetus and opportunity to overcome at least some of the existing barriers.
机译:本文的目的是检查和比较有关亚太地区国家的发病率,死亡率和生存率的可用数据。发病率数据来自GLOBOCAN 2008,其他在线数据源和各个癌症登记处。从世界卫生组织统计信息系统死亡率数据库获得的按年份划分的特定国家死亡率统计数据。所有发病率和死亡率均直接按照Segi世界标准人群的年龄进行标准化,并使用联合模型评估趋势。生存数据是从可获得的特定国家/地区的已发布报告中获得的。在2008年全球诊断出的所有前列腺癌中,约有14%(122,000)位于亚太地区(每100,000人口中有10人),其中四分之三的前列腺癌病例在日本(32%),中国( 28%)或澳大利亚(15%)。在亚太地区,还有约42,000人死于前列腺癌(每10万人中有3人死亡)。对于可获得发病率趋势数据的九个国家,八个国家最近显示前列腺癌发病率显着增加。相反,据报道,澳大利亚,日本和新西兰的前列腺癌死亡率最近有所下降,但其他几个国家的死亡率却有所上升。该地区大多数国家/地区缺乏基于人群的数据,这限制了研究人员了解和报告这种重要癌症的模式和分布的能力。政府和卫生计划者通常需要定量证据作为变革的动力。除非有广泛的承诺来改善前列腺癌数据的收集和报告,否则前列腺癌的负担可能会继续增加。在能力,政策和经验存在差异的国家之间加强知识交流,可以为克服至少某些现有障碍提供必要的动力和机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号